Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units under the company's deferred compensation plan.

Summary

• On March 31, 2025, Albert Bourla, Chairman & CEO of Pfizer Inc., acquired 24 phantom stock units.
• These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The price of the phantom stock units was $25.34.
• Following the transaction, Bourla directly owns 705,510 shares of common stock.
• The phantom stock units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The document is a neutral regulatory filing. The acquisition of phantom stock units is a standard part of executive compensation, indicating a stable and ongoing relationship between the executive and the company.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects part of Pfizer's executive compensation strategy.

Stakeholder Impact

• The acquisition of phantom stock units by the CEO aligns his interests with those of the shareholders, as the value of the units is tied to the company's performance.

Key Dates

Keywords

Form 4, Albert Bourla, Pfizer, Phantom Stock Units, Deferred Compensation, Beneficial Ownership, PFE